All In Biotech

Drug Trial Radar · NCT07726342

SMP-656 for HER2-Positive Advanced Breast Cancer

A Randomized, Open-Label, Dose-Optimization Phase II Clinical Trial to Evaluate the Efficacy and Safety of Single-Agent SMP-656 in Patients With HER2-Positive Locally Advanced or Metastatic Breast Cancer Who Progressed After Prior Treatment With HER2-Targeted Topoisomerase Inhibitor ADCs

Last checked: Nov 19, 2026Latest source record: Oct 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

60

Planned (sponsor's estimate)

Start

Aug 10, 2026

Primary completion

Jul 7, 2027

Study completion Oct 20, 2027

Sponsor

Sponsor type
Industry
First posted
Jul 24, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to learn if single-agent SMP-656 works to treat patients with HER2-positive locally advanced or metastatic breast cancer who have progressed after prior HER2-targeted topoisomerase inhibitor antibody-drug conjugate (ADC) treatment. It will also evaluate the safety of SMP-656 and identify the optimal dose for future trials. The main questions it aims to answer are: What is the objective tumor response rate (DOR, PFS, DCR, OS) of two different dose regimens of intravenous SMP-656? What are the side effects and safety risks of these two SMP-656 dose regimens? Which dose level achieves the best balance of anti-cancer activity and tolerability? This is a randomized, open-label, dose-optimization Phase II clinical trial. Participants will be randomly assigned 1:1 to receive one of two fixed doses of SMP-656 given intravenously once every 3 weeks. Participants will: Complete screening tests within 28 days before the first SMP-656 infusion to confirm eligibility Receive study treatment every 3 weeks until cancer progression, intolerable side effects, withdrawal, or other stopping criteria Have regular tumor imaging scans, physical exams, vital sign checks, and blood tests to monitor tumor response and safety Attend a safety follow-up visit 30 days after the last dose of SMP-656 Complete longer-term survival follow-up after the 30-day safety check Provide optional blood and tumor tissue samples for additional research studies

Conditions

  • HER2-positive Breast Cancer
  • Metastatic Breast Cancer
  • Locally Advanced Breast Cancer (LABC)

Interventions

  • SMP-656 InjectionDrug

    SMP-656 injection administered via intravenous infusion at a dose of 2.0 mg/kg once every 3 weeks (Q3W). Treatment continues until disease progression, intolerable toxicity, voluntary withdrawal, death, or trial termination.

  • SMP-656 InjectionDrug

    SMP-656 injection administered via intravenous infusion at a dose of 2.2 mg/kg once every 3 weeks (Q3W). Treatment continues until disease progression, intolerable toxicity, voluntary withdrawal, death, or trial termination.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Response Rate (ORR) assessed by Independent Review Committee (IRC)Time frame: From the date of first dose to the date of first radiological documentation of disease progression or death, whichever occurs first (up to 24 months)
  2. Recommended Dose in Pivotal Clinical TrialsTime frame: Through study completion, up to 24 months from first dose

Locations

15 sites in 1 country. Site status is shown where the registry gives one.

  • The Second Affiliated Hospital of Anhui Medical University

    Hefei, Anhui, China · Not yet recruiting

  • Beijing Cancer Hospital

    Beijing, Beijing Municipality, China · Not yet recruiting

  • Cancer Hospital, Chinese Academy of Medical Sciences

    Beijing, Beijing Municipality, China · Recruiting

  • Sun Yat-sen University Cancer Center

    Guangzhou, Guangdong, China · Not yet recruiting

  • The Fourth Hospital of Hebei Medical University

    Shijiazhuang, Hebei, China · Not yet recruiting

  • Henan Provincial People's Hospital

    Zhengzhou, Henan, China · Not yet recruiting

  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, Hubei, China · Not yet recruiting

  • Zhongnan Hospital of Wuhan University

    Wuhan, Hubei, China · Not yet recruiting

  • The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University

    Changsha, Hunan, China · Not yet recruiting

  • Zhongda Hospital, Southeast University

    Nanjing, Jiangsu, China · Not yet recruiting

  • Liaoning Cancer Hospital & Institute

    Shenyang, Liaoning, China · Not yet recruiting

  • Shandong Cancer Hospital and Institute

    Jinan, Shandong, China · Not yet recruiting

  • The First Affiliated Hospital of Xi'an Jiaotong University

    Xi’an, Shanxi, China · Not yet recruiting

  • Sichuan Cancer Hospital & Institute

    Chengdu, Sichuan, China · Not yet recruiting

  • Sir Run Run Shaw Hospital, Zhejiang University School of Medicine

    Hangzhou, Zhejiang, China · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.